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ABSTRACT
Introduction: Trastuzumab has become the standard treatment for both HER2-
positive early and metastatic breast cancer (HER2+ eBC or mBC) since its approval. 
The objective of the study is to estimate the benefit of adjuvant trastuzumab in the 
treatment of patients with HER2+ eBC in terms of life years gained (LYG) and disease-
free life years gained (DFLYG) since its approval in Spain in 2006. 
Results: 35,851 women make up the cohorts from 2006 to 2017. In the T 
(trastuzumab)+CT (chemotherapy) scenario, the sum of life years was 605,358 
(525,964 disease-free) versus 564,137 (489,916 disease-free) in the CT scenario, 
resulting in 41,221 LYG (36,048 disease-free) due to trastuzumab. The general 
population for the same age range would have generated 704,331 LY. The estimated 
incremental cost was 880.43 million€ (€24,558.13 per patient) from 2006 to 2035. 
The incremental cost-effectiveness ratios obtained were €20,644 and €23,960 per 
LYG and DFLYG, respectively.
Methods: An epidemiological model was developed with a time horizon until 
2035 and a 3% discount rate. The model compared two scenarios, with and without 
trastuzumab as adjuvant therapy. The effectiveness data to model the survival curves 
were obtained from BCIRG 006 study and direct costs were included.
Conclusions: Adjuvant trastuzumab has substantially improved the survival of 
patients with HER2+ eBC, contributing over 41,000 LYG to Spanish society (over 
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36,000 DFLYG) in a cost-effective manner. However, the sum of LYG with trastuzumab 
is still far from the LY estimated for the general population, supporting the need of 
further advances in HER2+ eBC.
INTRODUCTION
Breast cancer (BC) is considered a public health 
problem due to its high incidence, prevalence and 
mortality [1]. In fact, BC is the most frequent and fatal 
malignancy in Spanish women, with 27,747 cases 
diagnosed in 2015, and an age-adjusted mortality rate of 
15.9/100,000 [2]. 
Breast cancer is a very heterogeneous disease with 
a number of subtypes, based on the over-expression of 
hormone receptors or the overexpression or amplification 
of human epidermal growth factor receptor 2 (HER2). 
Both factors, hormone receptors and HER2, dictate the 
systemic treatment options of the patients. The prognosis 
and treatment of the disease depend on the stage (TNM 
classification: Tumor–Node–Metastases), site of 
metastasis and patient co-morbidities.
Historically, breast cancer patients with HER2 
positive tumours, which account for approximately 
15–20% of breast cancers, had a poorer prognosis than 
HER2 negative tumours. However, in women with 
HER2+ BC, the approval of the anti-HER2 monoclonal 
antibody trastuzumab in the year 2000 for the treatment 
of metastatic BC and in 2006 for the treatment of early 
BC considerably improved the prognosis of the disease - 
the drug becoming the standard of treatment for HER2+ 
BC in both the metastatic and early disease settings. 
The management of early BC is more homogeneous 
than that of metastatic BC, the latter being influenced 
by the previous treatment received, the disease burden, 
concomitant diseases, the site of metastasis, and the 
molecular phenotype of the metastatic tumour cells [3]. 
For this reason, and because it is a curative setting, the 
present analysis focuses on early stage disease.
Although there is ample evidence of the clinical 
benefits of trastuzumab as adjuvant therapy in HER2+ 
eBC [4–10], no studies have estimated the added value 
of the treatment in the real life clinical practice setting in 
Spain. 
Establishing the contribution of therapeutic 
procedures in real life clinical practice is one of the 
main challenges for both the healthcare system [11] and 
healthcare professionals [12].
The primary objective of the present study was to 
estimate the benefits of trastuzumab in the treatment of 
women with HER2+ eBC in terms of life years gained 
(LYG) and disease-free life years gained (DFLYG), since 
approval of the drug in Spain in 2006. As secondary 
objective, we aimed to estimate the additional cost for the 
healthcare system of treatment with trastuzumab, and to 
compare both parameters in added terms for the Spanish 
population during that period of time.
RESULTS
Epidemiological results
The incidence outcomes of the epidemiological 
model show an increase in the diagnosed cases of BC, 
from 21,132 new diagnoses in 2006 to 24,994 in 2017. 
This estimate is consistent with the data reported by 
GLOBOCAN [13], and slightly below the estimate of the 
Spanish Cancer Registries Network (REDECAN) (25,215 
new cases in 2015) [14]. Table 1 shows the evolution 
from 2006 to 2017 of the new cases of BC in general and 
the women with HER2+ eBC selected for analysis. The 
observed increase in diagnosed cases is attributable to 
variations in the gender and age pyramid of the Spanish 
population, which clearly aged over the entire period.
Primary objective: clinical results
The sum of life years (LY) of the women with 
HER2+ early BC during the analytical period for all 
the cohorts was 605,358 years in the trastuzumab + 
chemotherapy (T+CT) scenario, versus 564,137 in the 
hypothetical scenario of the absence of trastuzumab as 
adjuvant therapy (CT) since 2006. Therefore, the addition 
of trastuzumab to CT was estimated to afford a total of 
41,221 LYG for the Spanish society.
In order to place these results in context, the general 
population without HER2+ eBC for the same age range 
during the analytical period would have generated 704,331 
life years. This implies a difference of 98,973 life years 
between the general population without disease and the 
T+CT scenario, and of 140,194 life years between the 
general population and the CT scenario.
With regard to the sum of disease-free life years 
(DFLY), the total DFLY was 525,964 in the T+CT 
scenario, versus 489,916 in the CT scenario. Thus, the 
addition of trastuzumab to CT would afford a total of 
36,048 additional disease-free life years.
Figure 1 shows the cumulative life years and 
disease-free life years which the cohorts from 2006 to 
2017 would afford up until 2035 in both scenarios, as 
well as the difference between them, which represents the 
added clinical benefit of trastuzumab in real life clinical 
practice in Spain.
Considering the 41,221 additional life years which 
trastuzumab has afforded and will continue to afford 
Oncotarget4323www.oncotarget.com
Table 1: Estimation of the cohorts of women from 2006 to 2017 included in the model
Costs 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Total BC 
(25–90 years) 21,132 21,608 22,101 22,533 22,925 23,291 23,651 23,936 24,175 24,442 24,724 24,994
Target 
population* 2,664 2,724 2,787 2,841 2,891 2,937 2,982 3,018 3,249 3,377 3,173 3,208
*After selecting women with HER2+ early breast cancer; BC: breast cancer.
Figure 1: Cumulative results of life years and disease-free life years, follow-up until 2035. (A) cumulative life years in the 
CT and T+CT scenarios, cohorts 2006–2017 (follow-up 2035). (B) Cumulative life years gained (disease-free life years shown as dotted 
bars), cohorts 2006–2017 (follow-up 2035). Abbreviations: CT: chemotherapy; T+CT: trastuzumab plus chemotherapy; LYG: life years 
gained; DFLYG: disease-free life years gained.
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(follow-up until 2035), and taking into account that 35,851 
women have been treated to date (cohort 2006–2017), the 
life expectancy for a patient with HER2+ eBC will have 
increased 1.15 years. In the same way, the DFLYG with 
trastuzumab can be calculated. In this case, trastuzumab 
would extend the disease-free period by one year for each 
patient.
Secondary objective: economical results
The total direct costs associated to the sum of 
605,358 years of the T+CT scenario for all the cohorts 
(35,851 women in total) during the analytical period, 
considering the real use made of trastuzumab according 
to the market shares, would reach 1,384.02 million euros 
up until 2035 (€38,604.88 per patient including all direct 
costs). Most of these costs (61.5%) correspond to the 
pharmaceutical expenditure of the first year of treatment 
(851 million euros, €23,738 per patient).
In the hypothetical scenario where trastuzumab is 
absent, the total direct costs for all the cohorts (35,851 
women) would be 503.59 million euros (€14,046.75 per 
patient) up until 2035. In this scenario, the pharmaceutical 
expenditure corresponding to the first year of treatment 
would only represent 16.1% of the total cost (80.98 
million euros, €2,259 per patient) - most of the cost 
(75%) being concentrated in the management of disease 
relapses.
Therefore, the gain of 41,221 life years thanks 
to trastuzumab with CT has increased the direct costs 
by 880.43 million euros (€24,558.13 per patient) since 
approval of the drug in 2006, and considering follow-
up to 2035. Almost 88% (770.06 million euros) of this 
additional cost is due to the drug expenses corresponding 
to the first year of treatment. In contraposition to the 
above, the addition of trastuzumab to CT has reduced the 
cost of relapses by 12.82 million euros when comparing 
the T+CT scenario versus the CT scenario. Thus, the 
overcost of the first year (treatment with trastuzumab) is 
compensated over time thanks to the savings associated 
to the decrease in relapses and to the clinical benefits 
generated in terms of overall survival (OS) and disease-
free survival (DFS).
Secondary objective: cost-effect balance 
In this case, in order to strictly compare the 
incorporation of trastuzumab to standard CT, we do not 
consider the historical market share of trastuzumab in 
the T+CT scenario, i.e., in the T+CT scenario all the 
patients receive trastuzumab as adjuvant treatment instead 
of applying the real use percentage. If this were not so, 
the resulting incremental cost-effectiveness ratio (ICER) 
would not completely determine the incremental effects of 
adding trastuzumab, since a percentage of patients in the 
T+CT scenario would not have received the drug.
Table 2 shows the results of the cost-effectiveness 
analysis with ICERs of €20,644 /LYG and €23,960 /
DFLYG.
Results of the sensitivity analysis
The time horizon established in the base case 
ensures an average follow-up of 23.5 years. As sensitivity 
analysis, follow-up has been truncated in the year 2030, 
when the average follow-up is 19 years. 
The results of the rest of the scenarios alternative to 
the base case considered within the sensitivity analyses, 
along with the results of the univariate analysis, are 
reported in the Table 3.
Since the clinical benefits of trastuzumab in terms 
of LYG and DFLYG are obtained over time as DFS 
and OS increase versus CT alone, truncating the results 
in 2030 shows the greater impact upon the result of the 
base case, since the follow-up period needed to obtain the 
clinical benefits is shortened. The rest of the contemplated 
scenarios with an impact upon the clinical outputs of 
the model (LYG and DFLYG) have a more moderate 
influence.
With regard to the sensitivity analysis related to cost 
variables, quantifying influence upon the incremental cost 
associated to the T+CT scenario versus CT alone, those 
related to the estimation of recurrences or their cost exhibit 
an impact upon the economical outcomes of the base case 
(an additional 880.43 million euros) of between −0.7% 
(upper range of recurrence cost) and +12% (possibility of 
recurrences beyond 7 years). Varying the cost of CT has 
Table 2: Cost-effect balance results, assuming that all patients receive trastuzumab in the T+CT arm, follow-up until 
2035
T+CT only CT T+CT vs CT
Costs € 1,581,553,536 € 503,587,698 € 1,077,965,837
LY 616,354 564,137 52,217
DFLY 534,907 489,916 44,991
ICER (direct € /LY gained) € 20,644
ICER (direct € /DFLY gained) € 23,960
Abbreviations: CT: chemotherapy; T+CT: trastuzumab plus chemotherapy; LY: life years; DFLY: disease-free life years; 
ICER: incremental cost-effectiveness ratio.
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no effect upon the economical outcomes of the analysis, 
since it is administered equally in both scenarios. The 
variation of the temporal preference rate between 0% and 
5% has less impact upon the economical outcomes (+1.7 
and −0.9%, respectively) than on the results in terms of 
LYG and DFLYG. 
DISCUSSION
The results of the present analysis, estimating 
over 41,000 LYG thanks to the addition of trastuzumab 
to CT in HER2+ early breast cancer women in Spain, 
shows that the drug substantially improves the prognosis 
of patients with HER2+ eBC. The main contribution of 
this study is that it is the first to calculate both clinical 
and economical outcomes based on the combination of 
trastuzumab in adjuvant therapy for HER2+ eBC in the 
real life clinical practice setting in Spain, and on an added 
basis at population level.
Studies determining the life years that a given 
treatment has provided to society, are not very numerous. 
A similar model was developed in the United States to 
estimate the contribution of rituximab to the treatment of 
diffuse large B-cell lymphoma (DLBCL) [15]. Danese 
et al. estimated that rituximab in the period between 1999 
and 2013 contributed 200,278 LYG in the United States, 
with an incremental cost of 6.65 thousand million USD 
during that period. 
Although the primary objective of studies of this 
type is not to determine an incremental cost-effectiveness 
ratio (ICER) but to quantify the life years which a given 
treatment has provided to society in the real life clinical 
practice setting, a ICER may be estimated on the basis of 
the costs and reported additional clinical benefits afforded. 
These studies therefore may have some similarity to a 
conventional cost-effectiveness analysis. In any case, 
certain relevant aspects of these models differ considerably 
from the cost-effectiveness models. For example, the latter 
typically use Markov models with health states involving 
a hypothetical and homogeneous cohort of patients over 
a certain time horizon. In contrast, our model involves 12 
“real” cohorts (2006–2017) based on Spanish incidence 
data, and these cohorts are followed-up on to a certain 
year. In other words, not all the patient cohorts have the 
same follow-up time. For this reason, the time horizon 
of the analysis was projected to the year 2035, thereby 
ensuring a mean follow-up of over 20 years, and being 
able to correctly record the clinical benefits. In this type 
of cancer, it otherwise would not have been possible to 
register the clinical benefits in the more recent cohorts if 
the analysis had been truncated in the present year. 
In the specific case of HER2+ eBC, another 
important difference between our study and other 
published cost-effectiveness studies on trastuzumab is the 
fact that our model is the first to incorporate effectiveness 
data with a longer follow-up. The trastuzumab cost-
effectiveness studies identified in the literature extrapolate 
OS and DFS from the one- and two-year results of the 
BCIRG006 and HERA trials. This makes it necessary 
to view the comparison between our results and those 
of the previously published cost-effectiveness analyses 
with caution. Nevertheless, taking into account these 
differences and the methodological variability among the 
different studies, the cost-effectiveness ratios calculated 
in our article are consistent with the findings of most of 
the cost-effectiveness analyses on trastuzumab in early BC 
recorded in the systematic review published by Chan et al. 
(2009) [16].  
In view of the above, the main contribution of this 
study is that it quantifies the added clinical value afforded 
by trastuzumab in the treatment of HER2+ eBC in the real 
life clinical practice setting in Spain. A recent study has 
concluded that the use of trastuzumab in HER2+ eBC, 
together with appropriate screening, is able to modify the 
epidemiology of the disease, with a significant decrease 
in the number of patients with metastatic BC [17]. It 
therefore seems undeniable that trastuzumab has involved 
a change in the prognosis and treatment paradigm of BC - 
this affirmation being reinforced by the results of our study 
at a national population level. Nevertheless, on comparing 
the results with the general population corresponding 
to the same age range, it is seen that despite the great 
advance represented by the introduction of trastuzumab, 
a total of 98,973 years will still be lost due to HER2+ 
Table 3: Results of the univariate sensitivity analysis
SA parameters SA variation LYG with  Trastuzumab
DFLYG with  
Trastuzumab
Base case 41,221 36,048
Time horizon 2030 30,631 29,761
Efficacy data HERA 31,533 35,660
Parametric curves from the start (year 1) 40,086 33,383
Temporal preference rate 0% 52,648 43,675
Temporal preference rate 5% 35,662 32,278
Abbreviations: SA: sensitivity analysis; LYG: life years gained; DFLYG: disease-free life years gained.
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BC with follow-up of the cohorts to the year 2035. There 
consequently is still room for new therapies capable of 
further improving the health outcomes and the prognosis 
of patients with HER2+ early BC, bringing us closer to the 
cure of these patients.
In any case, the analysis is not without limitations. 
Some of them are inherent to pharmacoeconomic models 
of this kind, which are characterised by a degree of 
structural rigidity that can make it difficult to offer an 
appropriate representation of the clinical reality. For 
example, in order to establish the effectiveness of the 
treatments, the controlled clinical trials on trastuzumab 
have been used instead of real-world data studies, 
since the BCIRG006 (base case) and HERA (sensitivity 
analysis) studies have a longer follow-up, outside the 
protocol. The results of 25 years of experience with 
the treatment of early BC in Spain (patients enrolled 
between 1982 and 2015) have recently been reported, 
offering broad follow-up on the use of trastuzumab in 
real life clinical practice. The results obtained indicate 
an effectiveness of trastuzumab slightly greater than 
that observed in the open-label phases of the BCIRG006 
and HERA trials [18]. Another study has examined the 
impact of trastuzumab in 284 patients belonging to two 
cohorts (1996–2005 and 2006–2016), with results that 
are consistent with the above [19]. Nevertheless, in the 
developed model it proved necessary to extrapolate the 
data on DFS and OS. In the case of early BC, although 
data up to 11 years are available, survival is very high. 
This complicates parametrisation of the tails of the DFS 
and OS curves, since many patients have not presented the 
event in question (disease progression or death). 
Another limitation is the fact that trastuzumab is 
currently used as adjuvant treatment in practically all 
patients with HER2+ eBC, which makes it difficult to 
estimate the theoretical effectiveness of the “CT alone” 
treatment arm. Thus, in order to model the theoretical 
scenario without trastuzumab, use has been made of the 
control arms of the pivotal clinical trials, and it has been 
assumed that efficacy of the latter is maintained over the 
time horizon of the analysis. Furthermore, in the pivotal 
clinical trials of trastuzumab, there is crossover between 
the arms in the open-label phase, and this may cause 
underestimation of the efficacy of trastuzumab reported 
in those studies.
Another limitation is a consequence of the 
estimation of the annual relapses, where certain 
assumptions have had to be made. For example, based 
on the opinion of the experts, it has been assumed that 
there are no further recurrences beyond 7 years after 
the diagnosis. In addition, these can be calculated using 
different techniques [20], and we chose the option that 
best represents clinical practice according to the experts. 
The analysis also presents limitations regarding 
the costs. For example, in the mentioned recurrences it 
is difficult to establish a global cost comprising all the 
subsequent treatment lines, since patient management 
varies considerably among countries and regions, and 
also over time. Therefore, in our opinion, assuming the 
cost of the recurrences (equal for all the cohorts along the 
time horizon, and applied as one-off cost at the time of 
disease progression) to lie within the range obtained by 
Albanell et al. (2016) [21] using two alternative sources 
for the percentage of patients treated in each line, seemed 
to be an adequate approach.  
Another assumption was that the unit costs of CT 
remain constant and equal to the present costs (2017). As a 
result, the costs of CT can be expected to be overestimated 
in the first years of the analysis. Even so, since CT is 
administered in both scenarios, the impact of these results 
would be very low. We likewise did not contemplate the 
indirect costs associated to productivity losses among 
the women. These costs were included in the model, 
though an exploratory analysis showed their impact 
upon the economical outcomes to be very limited, taking 
into account the low active population percentage in the 
women corresponding to the age interval of the analysis. 
Therefore, despite slight lowering of the incremental cost 
associated to trastuzumab, we decided not to include these 
costs in the article. 
In order to minimise these limitations, we performed 
the sensitivity tests that confirmed the robustness of the 
results obtained. Furthermore, all the assumptions made, 
the parameters considered, and the results obtained were 
subjected to validation by the group of experts. 
In conclusion, our estimations show that adjuvant 
trastuzumab has substantially improved the survival of 
patients with HER2+ eBC, contributing over 41,000 
LYG to the Spanish society (over 36,000 DFLYG) in 
a cost-effective manner. However, the sum of LYG 
with trastuzumab is still far from the LY estimated for 
the general population, supporting the need of further 
advances in HER2+ eBC therapy.
METHODS
An epidemiological model was developed (using 
MS Excel 2010) of the benefits and costs associated to 
trastuzumab as adjuvant therapy in HER2+ eBC since 
approval of the drug for this indication in Spain in the 
year 2006. 
In annual cycles, the model was based upon the 
population incidence of early BC to obtain the selected 
number of newly diagnosed patients forming the model 
cohorts from 2006 to 2017 (target population), and estimate 
the incremental survival and incremental costs associated 
to the use of trastuzumab plus chemotherapy (T+CT), 
considering its percentage of real use, compared with a 
hypothetical scenario involving only chemotherapy (CT) 
in the absence of trastuzumab. 
The time horizon of the analysis extended to the year 
2035, thus ensuring a mean follow-up of these patients 
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treated between 2006–2017 of 23.5 years, in line with 
other cost-effectiveness studies in early BC, and allowing 
us to estimate the total contribution of the treatment [16]. 
An annual temporal preference rate of 3% was 
applied for both the costs and effects in future, i.e., referred 
to projection from the present time (2017) to 2035. 
A group of experts in BC (authors of the present 
article) contributed to design the model, validate the 
parameters and assumptions made, as well as the clinical 
feasibility of the results of the analysis.
Epidemiological data, target population
A Poisson regression model was developed to obtain 
the BC incidence rates in Spain specific of age, gender 
and year since 2006 to the present time, based on the 
Spanish BC incidence data available since 1996–2007 
obtained from GLOBOCAN [13]. Applying these rates to 
the Spanish population figures according to age (25–90 
years), gender and year published by the Spanish National 
Statistics Institute (INE), we calculated the number of 
new cases of BC diagnosed for the years of the analysis 
(2006–2017) [22].
After estimating the incident women with BC 
between 2006 and 2017, we selected those with early 
disease and amenable to having received trastuzumab, and 
which were thus regarded as the target population of the 
analysis. In this respect, we discarded those patients with 
in situ ductal carcinoma (18% [expert opinion]) and those 
with metastasis at the time of diagnosis (7% [23]). 
The prevalence of the HER2+ phenotype in these 
women was quantified based on the data of the Spanish 
Society of Pathology (SEAP) from 2013 to date. The 
percentage of HER2+ in these last years ranged from 16 
to 18%, assuming for the years before 2013 the figure 
reported that year (16.7%). According to the opinion of 
the experts, it was assumed that all the patients underwent 
testing.
Effectiveness
The clinical benefit of trastuzumab in combination 
with CT versus CT alone in the adjuvant therapy setting 
of HER2+ eBC was established on the basis of the long-
term outcomes of the randomized clinical trials on HER2+ 
eBC - the experts having considered that these studies with 
prolonged follow-up periods are representative of real life 
clinical practice in terms of the benefits associated to the 
treatment. In this regard, the BCIRG 006 study, the most 
recent data of which document 10 years of follow-up [5], 
was used as the base case for parametrising the overall 
survival (OS) and disease-free survival (DFS) curves used 
in the model. Therefore, the arm receiving anthracyclines 
followed by trastuzumab in combination with CT 
(AC→TH) in the BCIRG 006 study represented the T+CT 
scenario of the analysis, while the control arm of the 
BCIRG 006 study (AC→T) represented the hypothetical 
CT scenario of the analysis. The docetaxel, carboplatin 
and trastuzumab (TCH) arm of the BCIRG 006 study was 
not considered, since its use in routine clinical practice in 
Spain is more limited than that of the AC→TH regimen.
As the time horizon of the analysis was greater than 
the duration of follow-up in the BCIRG 006 study, it was 
necessary to adjust the parametric curves to the available 
efficacy data in order to extrapolate OS and DFS beyond 
the follow-up period of the mentioned study. Accordingly, 
parametric models were adjusted with Weibull distribution 
to the digitalized data of the Kaplan-Meier (KM) curves 
of the BCIRG 006 study, using the maximum likelihood 
estimation method [24] for both OS and DFS. Figure 2 
graphically displays the OS and DFS curves incorporated 
to the epidemiological model, differentiating the empirical 
data (digitalization of the KM curve) from parametrisation 
(Weibull model). 
The OS curves in turn were adjusted according 
to the Spanish overall mortality by age intervals [22] - 
only a slight influence in the tail of the curves being 
observed. Based on these OS curves, the model quantifies 
the added total life years of the interval 2006–2017 
to the time horizon of the analysis (year 2035), for the 
scenarios T+CT and CT. The difference between the two 
scenarios provides the life years gained (LYG) associated 
to trastuzumab. Based on this same reasoning, DFS 
provides the disease-free life years gained (DFLYG) with 
trastuzumab. 
Furthermore, the model allows us to estimate the 
number of progressions to the next line of treatment 
occurring each year, with an impact upon the analysis 
only in terms of costs. Two methods allow us to quantify 
the patients in progression each year, based on the area 
between the DFS and OS curves (partitioned survival 
model [PSM]) or based on calculation of the difference in 
patients that die or progress each cycle according to DFS 
minus the deaths according to OS each cycle (Markov 
cohort model) [20]. For the base case, progressions are 
quantified using the PSM approach. Based on the opinion 
of the experts, it has been assumed that recurrences occur 
in the first 7 years after the initial treatment of early BC.
Management of the disease
All the patients with early BC considered in the 
analysis received CT, usually accompanied by surgery. 
We consulted a number of European observational studies 
to establish the most commonly employed CT schemes 
[25–28]. Based on the distributions of the chemotherapies 
reported in these studies, the panel of experts established 
that the CT schemes which best represent clinical 
practice in Spain are TC (carboplatin + taxane) and 
AC-T (doxorubicin + cyclophosphamide + taxane), with 
a ratio of 25:75, respectively. Paclitaxel was the taxane 
most frequently used in AC-T, while docetaxel was the 
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taxane most commonly administered in the combination 
with carboplatin (with a ratio of 75:25 in both cases). The 
following CT scheme dosage regimens were used:
- paclitaxel 80 mg/m2 weekly during 12 weeks 
- doxorubicin 60 mg/m2 during 4 cycles plus
- cyclophosphamide 600 mg/m2 during 6 cycles
Since the aim of the analysis was to establish 
the real benefit of trastuzumab for Spanish society in 
HER2+ eBC, the model incorporated the market shares of 
trastuzumab since its approval for this indication, referred 
to both the intravenous (IV) formula and the more recent 
subcutaneous (SC) formula. Posologies for trastuzumab: 
Figure 2:  Disease-free survival (A) and overall survival (B) curves. (A) DFS curves for ACT and AC-TH arms. Bold lines represents KM 
data, and discontinuous lines the parameterization made to extrapolate the data. (B) OS curves ACT and AC-TH arms. Bold lines represents 
KM data, and discontinuous lines the parameterization made to extrapolate the data. Abbreviations: DFS: disease-free survival; OS: overall 
survival; CT: chemotherapy alone; T+CT: trastuzumab plus chemotherapy.
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-  Trastuzumab IV (trastuzumab 150 mg): 8 mg/
kg loading dose, followed by 6 mg/kg every 3 
weeks, given for 1 year
-  Trastuzumab SC (trastuzumab 600 mg): 600 mg 
every 3 weeks, given for 1 year
Figure 3 shows the assumed market share for 
adjuvant trastuzumab since 2006 (40%) up to present 
(almost all patients with HER2+ eBC).
Costs
The analysis considered the direct healthcare costs, 
classified into the following categories:
- Costs of initial treatment of HER2+ eBC
○  Pharmacological (both CT and trastuzumab 
IV or SC)
○ Administration (for IV dosing)
○ Monitoring and follow-up
- Costs after progression (recurrences)
The costs of the adverse events associated to the 
treatments of HER2+ eBC were not included in the 
analysis, since these costs are already considered within 
the cost of recurrences. Nevertheless, these costs are 
considered within the cost of recurrences (see below).
In relation to pharmacological costs we 
considered a cost per cycle calculated on the basis 
of the abovementioned CT schemes (with or without 
trastuzumab) and the hospital dispensation price (notified 
price to retailer [PTR]) [29]. In the case of drugs where 
the dose is conditioned to body weight or surface, the 
calculations were made considering an average weight 
of 66.4 kg or a body surface of 1.73 m2, respectively 
(corresponding to Spanish women between 45–54 years 
of age) [22].
On a conservative basis, for the cost of trastuzumab 
we applied the corresponding deduction set out in Spanish 
Royal Decree 8/2010 [30], according to the year of the 
cohort. In other words, no trastuzumab deduction was 
applied to the cohorts of 2006 to 2010, which predate the 
publication of RDL 08/2010. Between 2010 and 2014 
we applied 7.5%, and from 2014 onwards the current 
15% deduction (for IV administration) was applied. The 
SC formulation is subject to a 7.5% deduction since its 
marketing in late 2014. 
As the variations of the real prices of some of the 
drugs used in CT from 2006 to date are not precisely 
known, we considered the current prices for all the cohorts - 
this implying a conservative position, since the costs of 
CT in the initial cohorts are probably underestimated. 
The intravenous treatments moreover have an 
associated administration cost of €211.64 corresponding 
to the visits to the day hospital, obtained from the eSalud 
healthcare costs database [31]. This cost has been adjusted 
for each cohort of the model according to the inter-annual 
variations in the consumer price index (CPI) obtained 
from the INE [32].
As monitoring and follow-up costs we only 
included the cost associated to the performance of 3-4 
echocardiograms during the year of treatment with 
trastuzumab and 1 echocardiogram yearly thereafter, the 
unit cost being €133 [31], likewise adjusted according 
to the variation in CPI for each year. The panel of 
experts considered that, apart from the echocardiogram 
Figure 3: Market shares of trastuzumab as adjuvant therapy in early BC. Blue part of the bar represents market share of 
trastuzumab. Since 2015, within market share of trastuzumab, spotted part represents SC formulation while smooth part represents IV 
formulation. Abbreviations: IV: intravenous; SC: subcutaneous.
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assessment, there is no differential follow-up of the 
patients according to whether CT combined with 
trastuzumab is received or not.
Supplementary Table 1 shows the costs of the initial 
treatment of HER2+ eBC applied during the first year of 
each cohort, for each of the two analytical scenarios. 
The cost of the recurrences was entered in the 
model as one-off cost, i.e., the total cost considered for 
recurrent disease is fully imputed to the year in which 
disease progression occurs. In order to estimate total cost 
after disease progression, we used the cost analysis made 
by Albanell et al., 2016 [21], which estimated the cost of 
the loco-regional and metastatic relapses (up to a fifth 
line of treatment). The estimates considered the direct 
pharmacological and non-pharmacological costs (visits, 
test, hospital admissions, etc.) and the adverse events 
associated to the treatments. Within pharmacological 
costs, pertuzumab in combination with trastuzumab was 
incorporated from 2014 until 2017, and cost of TDM1 
from 2015 until 2017. Based on the cost results of this 
study, and considering the percentages of patients that 
receive each treatment line in the analysis of Albanell 
et al., 2016 [21] and also the observational study published 
by Colomer et al., 2016 [33], we obtained weighted 
costs between €157,658 and €208,682 associated to the 
recurrences. Therefore, for the base case we used the average 
of both figures (183,170 €) as total relapse cost, employing 
these references as ranges of the sensitivity analysis.
Sensitivity analysis
In order to evaluate the uncertainty of some of 
the variables used in the analysis and to determine the 
robustness of the model and the results obtained, we 
performed a number of deterministic sensitivity analyses, 
contemplating both methodological alternatives to the 
base case and modifying certain parameters of the model 
within a given range.
The following sensitivity analyses were considered:
- Time horizon: results truncated in 2030
- Efficacy data of the HERA study [6]
- Parametric curves from the start (year 1)
-  Estimation of recurrences according to the 
Markov model approach
- Possibility of relapses after more than 7 years
-  Temporal preference rate for effects and costs 
(0–5%)
-  Unit costs of IV administration and 
echocardiogram (± 25% over base case value)
- Chemotherapy cost (± 25% over base case value)
- Cost of recurrences (range €157,000 - €209,000)
Abbreviations
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